Monthly Prescribing Reference

FDA Greenlights First CAR T-Cell Therapy for Marginal Zone Lymphoma

Credit: Bristol Myers Squibb. The approval was based on data from the MZL cohort of the open-label, single-arm, phase 2 TRANSCEND FL trial. Breyanzi is prepared from the patient’s T cells, which are ...
Business Wire

Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene ...

95.5% of patients with relapsed or refractory marginal zone lymphoma (MZL) treated with lisocabtagene maraleucel (liso-cel) achieved a response, with 62.1% achieving complete response and 88.6% ...
The American Journal of Managed Care

What Would Make Therapy Last? How About 2 Targets Each on B Cells and T Cells?

The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
Seeking Alpha

Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for ...

Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results from MZL cohort of TRANSCEND FL presented at ICML in ...